Dr. Corash bought 46,000 shares in the open market on August 10th around 2.44 and another 46,000 shares on August 11th with an average price of 2.46 - - - This is a man that has never sold any of his shares from his buying frenzy of several years ago this same month. And when he has exercised option grants, he has actually paid for the taxes out of his own wallet, rather than simply surrender the equivalent amount of shares.
Presenting at Baird and Cantor Fitz next month.
All technical indicators a buy and what a chart. A close above 2.65 and I can make a case for 3.35 with trend lines. One of the best looking charts in my universe.
ACRX has an Oct 12th PDUFA date... Roth Capital Price Target is $13...
this weeks quarterly fundholder filings shows that Wells Fargo sold out of 2.2 million shares, and now holds 1.1 million. New holders shows Delta Lloyd Management with 500,000 and more importantly, Stevie Cohen's "Point72 asset management with 410,000 shares. #2 fundholder BlackRock added 104,000 shares while Baker Bros have yet to report, nor has Primecap, Vanguard, or Elk Creek yet.
big money is looking for new investments......look out above......
Cerus' INTERCEPT Platelet systems, designed to mitigate platelet transfusion infection risks (an under-met need), are beginning to undergo successful market pen
Taylor, how do you square your dire predictions with this little point???? On 8/10/2017 1:02:15 PM EDT
By a News Reporter-Staff News Editor at Biotech Business Week -- Cerus Corporation (NASDAQ: CERS) announced the signing of two, new, expanded contracts with Etablissement Francais du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to help support the roll-out to new regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in all EFS regional centers (see also Biotechnology Companies).
"We are proud that our decade long relationship with the EFS has led to an expanded supply agreement that supports a new standard of care," said William 'Obi" Greenman, Cerus' president and chief executive officer. "Currently, approximately 10% of the annual platelet production in France is treated with the INTERCEPT system. We look forward to working with EFS to implement pathogen reduction throughout their system. In support of this broad roll-out to new regions, we plan to ramp up production of INTERCEPT Platelet kits to ensure ample supply," continued Greenman.
In January, the EFS was informed of the Ministry of Health's decision that the INTERCEPT Platelet system should be deployed for the control of bacterial infections transmitted by transfusion, in accordance with a prior December 2016 recommendation by France's regulatory authority, ANSM, the French National Agency for Medicines and Health Products Safety.
Nice try though Taylor
Now that Baker Bros have sold more than 21% of their shares I suggest that you sell any shares you have fro what you can get. Dumped all of my holdings and bit the bullet, tough to loose 30K but better than to loose even more. There is no way they will be able to sell shares for more than $2 something and the cash bleed is atrocious. With the number of new shares there is no chance of becoming profitable by 2019.
Aaron and Ameen are sisters from the same uncle
This is why a long term view is very good with Cerus, from the Q2 report....
"With the anticipated contributions from the EFS contract, improving gross margins, the flexibility to fund the anticipated EFS and other commercial growth from our new debt facility, and our focus on controlling operating expenses and utilizing existing Cerus resources to execute under our BARDA contract, we expect operating burn to come down meaningfully." "Our red cell development program is moving forward in both the EMEA and the US and we've added INTERCEPT Cryo as new program in our development portfolio that we believe has the potential to drive significant revenue growth in the intermediate timeframe. Finally, we are instituting a disciplined approach to manage our cash burn while we work to deliver both revenue growth and development progress."
Back from the brink.
aaron the SCHMUCKAFLUCK !!!
250 mil mixed shelf and 6 mil employee options at 2,27 announced on Friday after close. If the stock is not down after earnings and that announcement, next stop 3.
Back to $3?
They believe they can make their cash last. And I believe them to a point. They can make BARDA monies stretch to maintain key employees and keep the lights on while they reduce overhead and support the deliberate and inevitable ramp of their products. Unfortunately, they will have to sell shares to raise cash at some point. I'd say the hope is they can hold out until share price rises somewhat. Can they hold out until RBC CE submission more than a year from now? And will the sharks let the SP rise knowing a raise is coming?
everything is always anticipation or down the road with CERS... That is not just the trend but history. One other thing that is a trend: Pump & Dump. This time with a $2.5 ceiling. Ouch. Here come the $1s. Next round of merit based options awards will be in $1s. Now that is ironic, I thought those options were for building shareholder value not destroying it. Great work Obi, Kevin and team!
Great news today. Cerus received an additional $40 credit facility from their lender and have just drawn $30 mil with another $10 mil available in the future. This takes a lot of pressure off Cerus to sell more shares to finance their growth.
More important, the credit provider has thoroughly reviewed Cerus before making this loan and is comfortable in loaning money to them. This takes a lot of pressure off Cerus.
Keep in mind the $ has fallen a lot re the Euro this year. When they convert their European results to $ the results should be much better than at YE 2016 and Q1 2017.